

Please type a plus sign (+) inside this box → ☐

PTO/SB/8B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.


Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	09/847,960
				Filing Date	May 2, 2001
				First Named Inventor	SWIFT, Susan E.
				Group Art Unit	1645
				Examiner Name	
Sheet	1	of	1	Attorney Docket Number	A-69332-1/RMS/AXG

RECEIVED

MAR 14 2002

TECH CENTER 1600/2900

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
ES	C1	Berton MT, Vitetta ES. IL-4-induced expression of germline gamma 1 transcripts in B cells following cognate interactions with T helper cells. Int Immunol. 1992 Mar;4(3):387-96.		
	C2	Berton MT, et al. Synthesis of germ-line gamma 1 immunoglobulin heavy-chain transcripts in resting B cells: induction by interleukin 4 and inhibition by interferon gamma. Proc Natl Acad Sci U S A. 1989 Apr;86(8):2829-33.		
	C3	Jardieu P. Anti-IgE therapy. Curr Opin Immunol. 1995 Dec;7(6):779-82.		
	C4	Shields RL, et al. Inhibition of allergic reactions with antibodies to IgE. Int Arch Allergy Immunol. 1995 May-Jun;107(1-3):308-12		
	C5	Turaga PS, Berton MT, Teale JM. Frequency of B cells expressing germ-line gamma 1 transcripts upon IL-4 induction. J Immunol. 1993 Aug 1;151(3):1383-90.		
	C6	Warren WD, Berton MT. Induction of germ-line gamma 1 and epsilon Ig gene expression in murine B cells. IL-4 and the CD40 ligand-CD40 interaction provide distinct but synergistic signals. J Immunol. 1995 Dec 15;155(12):5637-46.		

Examiner Signature		Date Considered	Aug 15, 2003
--------------------	---	-----------------	--------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English Language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.